Warren Casey

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/828405/publications.pdf

Version: 2024-02-01

22	812	567281	610901
papers	citations	15 h-index	24 g-index

26	26	26	1119
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Rethinking chronic toxicity and carcinogenicity assessment for agrochemicals project (ReCAAP): A reporting framework to support a weight of evidence safety assessment without long-term rodent bioassays. Regulatory Toxicology and Pharmacology, 2022, 131, 105160.	2.7	13
2	Evaluation of Variability Across Rat Acute Oral Systemic Toxicity Studies. Toxicological Sciences, 2022, 188, 34-47.	3.1	22
3	Assessing chemical carcinogenicity: hazard identification, classification, and risk assessment. Insight from a Toxicology Forum state-of-the-science workshop. Critical Reviews in Toxicology, 2021, 51, 653-694.	3.9	10
4	An integrated chemical environment with tools for chemical safety testing. Toxicology in Vitro, 2020, 67, 104916.	2.4	37
5	Validation of the OptiSafeâ„¢ eye irritation test. Cutaneous and Ocular Toxicology, 2020, 39, 180-192.	1.3	6
6	Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation. Regulatory Toxicology and Pharmacology, 2020, 113, 104624.	2.7	22
7	An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. Regulatory Toxicology and Pharmacology, 2020, 112, 104592.	2.7	108
8	Increasing the use of animal-free recombinant antibodies. ALTEX: Alternatives To Animal Experimentation, 2020, 37, 309-311.	1.5	4
9	Reflections on the progress towards non-animal methods for acute toxicity testing of chemicals. Regulatory Toxicology and Pharmacology, 2019, 102, 30-33.	2.7	32
10	United States regulatory requirements for skin and eye irritation testing. Cutaneous and Ocular Toxicology, 2019, 38, 141-155.	1.3	14
11	Status of acute systemic toxicity testing requirements and data uses by U.S. regulatory agencies. Regulatory Toxicology and Pharmacology, 2018, 94, 183-196.	2.7	58
12	Recommendations toward a human pathway-based approach to disease research. Drug Discovery Today, 2018, 23, 1824-1832.	6.4	23
13	Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology, 2017, 385, 48-58.	4.2	24
14	Multivariate models for prediction of human skin sensitization hazard. Journal of Applied Toxicology, 2017, 37, 347-360.	2.8	58
15	Systems biology for organotypic cell cultures. ALTEX: Alternatives To Animal Experimentation, 2017, 34, 301-310.	1.5	10
16	Advancing toxicology research using in vivo high throughput toxicology with small fish models. ALTEX: Alternatives To Animal Experimentation, 2016, 33, 435-452.	1.5	48
17	International Harmonization and Cooperation in the Validation of Alternative Methods. Advances in Experimental Medicine and Biology, 2016, 856, 343-386.	1.6	16
18	Validation of Alternative In Vitro Methods to Animal Testing: Concepts, Challenges, Processes and Tools. Advances in Experimental Medicine and Biology, 2016, 856, 65-132.	1.6	31

#	Article	IF	Citations
19	Application of Reverse Dosimetry to Compare In Vitro and In Vivo Estrogen Receptor Activity. Applied in Vitro Toxicology, 2015, 1, 33-44.	1.1	19
20	Performance of the BG1Luc ER TA method in a qHTS format. ALTEX: Alternatives To Animal Experimentation, 2015, 32, 287-96.	1.5	4
21	Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway. Scientific Reports, 2014, 4, 5664.	3.3	167
22	Non-animal replacement methods for human vaccine potency testing: state of the science and future directions. Procedia in Vaccinology, 2011, 5, 16-32.	0.4	23